Jim Cramer says this healthcare stock is still a buy. Plus, what to do with BNY

Warmer-than-expected September inflation data weighed on the S&P 500 and Nasdaq Wednesday, alongside continued semiconductor weakness; the semiconductor ETF was on pace for a seventh straight day of declines. Defensive sectors including healthcare and consumer staples attracted flows, with Eli Lilly up more than 3.5%. Bank shares also fell after earnings: Bank of America dropped 7.5% after missing revenue expectations and receiving a Treasury Department money-laundering fine, while State Street fell nearly 8%.

Analysis

The more durable signal is rates sensitivity, not the day’s sector tape: a hotter inflation print can push yields higher and compress long-duration multiples, putting semiconductors and cybersecurity under pressure even without company-specific deterioration. If yields stabilize, some of that relative underperformance could reverse quickly; avoid treating one session’s rotation as a fundamental downgrade to CRWD or PANW.

In banks, separate BAC’s company-specific regulatory penalty and revenue miss from the broader read-through. STT’s reaction raises the bar for BNY’s report: weakness in fee trends, flows, or expense guidance would make the pressure more than sympathy trading. Conversely, a clean BNY update would argue against extrapolating one peer’s selloff across custody banks. The renewed CVS agreements with CAH and MCK support continuity, but do not establish improved distributor economics; verify contract terms and margins before assigning upside.

Over 1–3 months, the key catalyst is whether inflation and yields keep repricing rate-sensitive growth versus defensives. Over 6–18 months, healthcare and consumer staples only merit a structural premium if earnings resilience persists; defensive inflows alone are not enough. The contrarian risk is chasing defensives after they have already outperformed while selling growth into a potentially temporary rates shock. Falsify the growth-pressure thesis if yields ease and semiconductor/cyber earnings expectations hold; strengthen it if inflation reaccelerates and guidance revisions broaden.

Key Decisions for Investors

• Avoid a broad directional trade off this single session. For a tactical relative-value setup, consider a small long KMB versus short a diversified semiconductor exposure only if real yields continue rising; reduce or exit if yields reverse and the growth complex stabilizes. This is a rates/flow expression, not a view that KMB has newly improved fundamentals.
• Do not buy BNY ahead of its results solely because the selloff may be sympathy-driven. Reassess after the report: constructive fee/flow and expense commentary would support a measured add; deterioration would argue against averaging down and could pressure STT and other custody peers.
• Treat BAC’s weakness as partly idiosyncratic until other bank reports confirm broader revenue or credit stress. Do not automatically extend it to WFC or GS; monitor earnings guidance and credit metrics for confirmation before adding financial-sector exposure.
• Keep CRWD and PANW on a watchlist rather than shorting them on rotation alone. A sustained rise in yields plus negative earnings revisions would support further downside; easing yields and stable forward guidance would invalidate the tactical underweight.